Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (3MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-542579
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.54257
Zusammenfassung
Background Graft rejection and chronic CNI toxicity remain obstacles to organ transplant success. Current formulations of tacrolimus, such as Prograf® and Advagraf™, exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability. As dosing non-compliance can result in graft rejection, the once daily formulation of tacrolimus, Advagraf™, was ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags